Member Info for dallo

Ars,

Hopefully Puretech will RNS this information later today when US markets open

Cheers

Great update

I hope that is the last we hear from Lambo.

Are not supported by her response, I should say.

Joshing

Well my response to you is that if a Liquidator is appointed or a massive discounted placing is in the offing, then Lisa's reply and comments would be totally egregious and misleading in the extreme so my point is that the horror scenarios speculated on by some posters here are supported by her response to me.

Having said that I have been totally fooled and shafted by other AIM companies Investor Relations correspondence in the past but for now I trust Lisa Badderoon.

I have received a reply to my email from Lisa the full details I will not go into but I would advise any genuine investors here to contact Lisa and she will respond if you are on the shareholders register.

The only comments I would make is that Lisa referred to the detailed update issued by the company last December and to the current collapse in a host of AIM Biotech companies which , like Immupharma, bear no relation in many cases to the valuation of the assets in these companies.

Finally she said the Board will look to issue further updates in the near future and as the Directors are shareholders themselves , they are committed to increasing the value of the company's shares to reflect the true value of its assets.

I hope that is some assistance to genuine investors here as I trust Lisa and her integrity.

ATB

I am in no doubt an RNS is imminent but whether we will like it is another question altogether.

Fingers crossed

Even Lisa is not responding to my emails which is very unusual.

Given the amount of emails to the company in the past few days from myself and other shareholders, I am expecting a major RNS tomorrow or Tuesday at the latest.

Wild tiger

So you have made over £100, 000 on Immupharma.

Well done I didn't think there were any winners in this debacle!

I am always a sucker for good luck stories ( or tall tales !)

Wildbunch

I also emailed Lisa requesting an urgent response by the company to the total collapse in the company's share price driven in part by deep uncertainty over its financial position.

Lambo is quite correct in saying Immupharma will not be able to raise any funds via a share issue with SP heading to .5p so it will have to pull a large rabbit out of the hat somehow.

I have emailed Lisa regarding the collapse in the SP today and said it is disgraceful that shareholders are kept in the dark as we lose all our investment.

Capitulation now

Awful after 8 years .

Dealing at .85p

Lambo

For what it is worth the market wants to crush the share price now with no support whatsoever.

Not looking good sadly.

Moneymule I should say

Moneymore

Immupharma has used part of the £62m losses in obtaining R&D Tax Credit relief but a major element of the losses remain untouched ( strangely I think the unused amount may be nearer £50m , a figure quoted by Alex who appears to know an awful lot about Immupharma..I wonder???)

Pokerchips

The figure for accumulated losses forward for possible set off of tax liabilities against future profits are a scary £62m as at the end of June 2023.

If a profitable acquirer was to take over Immupharma and merge its business, it would have a significant tax shield derived from Immupharma's losses forward.

Oldernowiser

Good to see you joining the Puretech chat..we are both involved in Immupharma.

However Puretech is a cash rich exciting Pharma company with major catalysts in the coming months.

Immupharma is interesting with risk / reward of a different dimension to Puretech.

Best of luck

Alex

As a long term investor for over 8 years now with 3 million shares at an average of 10p I have posted regularly on the positives of Immupharma in terms of its upcoming 2 Phase 3 trials , its deferred tax losses, its debt free balance sheet and its French scientific operations , low cost management structure, valuable patents and its potentially lucrative investment in Incanthera et al.

I have also referenced the growth of the Alora group under the leadership of Art Deas with its 6 subsidiary companies , including our Lupuzor partner Avion and its valuation of over $1 billion .

Alora has already invested £1.1m in Immupharma at 11p and may be interested in a further investment now that the Lupuzor trial is about to commence.

However I have stressed to Lisa that radio silence from the company is having a hugely negative effect on investor confidence and allowing small trades to drive the SP down.

Hopefully the company has some positive news in the pipeline to assuage our concerns because a requirement for an additional funding of £1/2 million is petty cash to the interested parties here including the Alora Group.

Lisa is very approachable as the company's IR contact so I urge investors to contact her.

ATB

Wow

After months of minimal discussion , the board has ignited all of a sudden with contributions from new posters some of whom suggest they are very close to the company in their analysis and rebuttal of Lambo's

repeated claims of another death spiral placing or worse.

Surely Uncle Tim is not involved in this sudden explosion of chat!!

Hopefully the share price can mirror the volume of postings and get moving upwards

At the moment the market is not interested as this deathly silence from the company continues.

Redduke

As we all know about the litigious nature of corporate life in the US, law suits from a few small investors ( or large in most cases) in acquisition/ takeover transactions is almost the norm.

At the EGM of Karuna in 2 weeks time, the Directors will be duty bound to answer all relevant questions in relation to the takeover proposal from BMS and justify their recommendation to accept the offer.

If a majority of shareholders approve the transaction at the EGM then any litigation by a disgruntled few shareholders faces an uphill battle.

If it is a ploy by the litigants to get the Directors to improve the terms of the sale, then perhaps the Directors may have a few sweeteners to offer at the EGM even though this is probably unlikely.

I can't remember any major acquisition in the US that didn't involve some ambulance chasing by lawyers to try and get a bit extra for clients in the deal and thus garner fat fees for them.

Nothing for us to worry about imho.